Corey Goodman, venBio
February 12, 2020 10:02 AM EST
Financing
Startups
R&D

Corey Good­man mar­shals $105M mega-round for his CD47 up­start, look­ing to break new ground in PhII

John Carroll

Editor & Founder

Corey Good­man has put an­oth­er notch on his ven­ture belt, ring­ing up a $105 mil­lion mega-round for his CD47 start­up ALX On­col­o­gy.

Fu­el­ing a start­up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times